ADNI: Alzheimer's Disease Neuroimaging Initiative

Summary

The purpose of this study is to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). This information will aid future clinical trials by providing a standard assessment tool to measure the effects of treatments being studied.

Conditions

• Alzheimer's Disease

Interventions

PROCEDURE

Magnetic Resonance Imaging (MRI)

MRI scans

PROCEDURE

Positron Emission Tomography (PET)

PET scans

PROCEDURE

Lumbar Puncture (LP)

collection of cerebrospinal fluid

Sponsors & Collaborators

• Northern California Institute of Research and Education

  collaborator OTHER

• National Institute on Aging (NIA)

  collaborator NIH

• National Institute for Biomedical Imaging and Bioengineering (NIBIB)

  collaborator NIH

• Foundation for the National Institutes of Health

  collaborator OTHER

• Alzheimer's Drug Discovery Foundation

  collaborator OTHER

• Alzheimer's Association

  collaborator OTHER

• Alzheimer's Disease Cooperative Study (ADCS)

  lead OTHER

Principal Investigators

• Michael W. Weiner, MD · University of California, San Francisco

• Ronald Petersen, MD, PhD · Mayo Clinic - Rochester, Minnesota

• Paul Aisen, MD · University of California, San Diego

Eligibility

Min Age

55 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

Yes

Timeline & Regulatory

Start

2005-07-31

Primary Completion

2011-06-30

Completion

2011-06-30

Countries

• United States
• Canada

Study Locations